FDA Selects EMD to Present at Psychedelic Medicines Hearing
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Emyria Ltd has been selected by the U.S. Food and Drug Administration to present at a public hearing on psychedelic medicines, highlighting its experience in treating patients with psychedelic-assisted therapies in Australia. This opportunity allows Emyria to contribute to discussions on provider training, patient safety, access, and data collection relevant to the future therapeutic use of psychedelic drugs. The hearing is scheduled to take place at the FDA’s White Oak Campus, providing Emyria a platform to showcase its operational experience in the world's largest healthcare market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Emyria
- Emyria Set to Launch First NSW Clinic
- Appendix 4E & Annual Financial Report Year End 30 June 2026
- Emyria Unlocks Treatment Capacity
- June 2026 Quarterly Activities Report and Appendix 4C
- Emyria Depression Program Shows Positive Results
Later from Emyria
- Emyria Successfully Opens First NSW Empax Clinic
- September 2026 Quarterly Activities Report and Appendix 4C
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria